Microinvasive breast carcinoma is a subcategory of ductal carcinoma in situ (DCIS) tumor, and it has a good prognosis. It is less likely to metastasize, and typically it responds well to treatment.
Microinvasive breast carcinoma has a good prognosis.
What is DCIS?
The language surrounding breast cancer can be confusing.
A straight DCIS (ductal carcinoma in situ) tumor means it is confined exclusively to the milk duct tissue. It has not spread (invaded) outside.
Microinvasive
Microinvasive breast carcinoma is known by multiple abbreviations.
Microinvasive breast carcinoma is known by multiple acronyms, including MIC, MICB, and DCISM. "Microinvasive" indicates the size (less than 1.0 mm) and the fact that 10 percent or less has left the duct tissue (the original tumor site).
Treatment
Treatment is individual.
Treatment is individual based on tumor typing and staging, and on collaboration between doctor and patient. However, Drs. Mattia Intra and Stefano Zurrida say sentinel lymph node biopsy should be considered standard (2002).
Outcome Influences
Many factors influence outcome.
Age at diagnosis, family history, size of tumor, spread, condition of lymph nodes, and other health issues influence the outcome. The treatment protocols chosen can influence the long-term prognosis.
Expert Insight
Talk to your doctor about prognosis.
"MIC as defined has a good prognosis. It has a different biology than T1 invasive carcinoma with 90 percent DCIS, which may progress and cause death. Large tumors with multiple foci of microinvasion may have metastatic potential." (Drs. Ruth Padmor & Barbara Fowble, et. al., 2000)
Tags: good prognosis, Microinvasive breast, breast carcinoma, breast carcinoma, breast carcinoma known, carcinoma known
